BR112022011666A2 - Receptor de antígeno quimérico, ácido nucleico isolado, vetor, célula imune, composição farmacêutica, método de tratamento de uma doença, anticorpo - Google Patents
Receptor de antígeno quimérico, ácido nucleico isolado, vetor, célula imune, composição farmacêutica, método de tratamento de uma doença, anticorpoInfo
- Publication number
- BR112022011666A2 BR112022011666A2 BR112022011666A BR112022011666A BR112022011666A2 BR 112022011666 A2 BR112022011666 A2 BR 112022011666A2 BR 112022011666 A BR112022011666 A BR 112022011666A BR 112022011666 A BR112022011666 A BR 112022011666A BR 112022011666 A2 BR112022011666 A2 BR 112022011666A2
- Authority
- BR
- Brazil
- Prior art keywords
- bcma
- antibody
- antigen receptor
- chimeric antigen
- binding
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 210000002865 immune cell Anatomy 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 abstract 5
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 abstract 5
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 abstract 5
- 239000000126 substance Substances 0.000 abstract 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
RECEPTOR DE ANTÍGENO QUIMÉRICO, ÁCIDO NUCLEICO ISOLADO, VETOR, CÉLULA IMUNE, COMPOSIÇÃO FARMACÊUTICA, MÉTODO DE TRATAMENTO DE UMA DOENÇA, ANTICORPO. Trata-se de um receptor de antígeno quimérico (CAR) que compreende um polipeptídeo que compreende um domínio de ligação ao antígeno extracelular que compreende uma primeira porção química de ligação a BCMA e uma segunda porção química de ligação a BCMA, em que a primeira porção química de ligação a BCMA é um primeiro anticorpo de domínio único anti-BCMA, e a segunda porção química de ligação a BCMA é um segundo sdAb anti-BCMA; e em que cada um dentre o primeiro e o segundo sdAb é um domínio VHH.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019125681 | 2019-12-16 | ||
PCT/CN2020/112182 WO2021037222A1 (en) | 2019-08-28 | 2020-08-28 | Engineered t cells and methods of producing thereof |
PCT/CN2020/112181 WO2021037221A1 (en) | 2019-08-28 | 2020-08-28 | Nef-containing t cells and methods of producing thereof |
PCT/CN2020/136570 WO2021121228A1 (en) | 2019-12-16 | 2020-12-15 | Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022011666A2 true BR112022011666A2 (pt) | 2022-12-20 |
Family
ID=76477076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022011666A BR112022011666A2 (pt) | 2019-12-16 | 2020-12-15 | Receptor de antígeno quimérico, ácido nucleico isolado, vetor, célula imune, composição farmacêutica, método de tratamento de uma doença, anticorpo |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230058669A1 (pt) |
EP (1) | EP4077398A4 (pt) |
JP (1) | JP2023505719A (pt) |
KR (1) | KR20220116221A (pt) |
CN (1) | CN115052901A (pt) |
AU (1) | AU2020404272A1 (pt) |
BR (1) | BR112022011666A2 (pt) |
CA (1) | CA3163794A1 (pt) |
IL (1) | IL293862A (pt) |
MX (1) | MX2022007222A (pt) |
WO (1) | WO2021121228A1 (pt) |
ZA (1) | ZA202206438B (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
WO2023064909A1 (en) * | 2021-10-14 | 2023-04-20 | Nighthawk Biosciences, Inc. | Bifunctional anti-pathogenic agents |
CN116284385A (zh) * | 2021-12-07 | 2023-06-23 | 信达细胞制药(苏州)有限公司 | 靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用 |
WO2024022509A1 (en) * | 2022-07-29 | 2024-02-01 | Nanjing Legend Biotech Co., Ltd. | Methods for promoting persistence of cell therapy |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015292590B2 (en) * | 2014-07-24 | 2020-01-16 | 2Seventy Bio, Inc. | BCMA chimeric antigen receptors |
DK3230321T3 (da) * | 2014-12-12 | 2019-10-28 | Bluebird Bio Inc | Kimære bcma-antigenreceptorer |
CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
WO2019000223A1 (en) * | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
-
2020
- 2020-12-15 CN CN202080092743.XA patent/CN115052901A/zh active Pending
- 2020-12-15 US US17/784,489 patent/US20230058669A1/en active Pending
- 2020-12-15 BR BR112022011666A patent/BR112022011666A2/pt unknown
- 2020-12-15 JP JP2022536487A patent/JP2023505719A/ja active Pending
- 2020-12-15 IL IL293862A patent/IL293862A/en unknown
- 2020-12-15 AU AU2020404272A patent/AU2020404272A1/en active Pending
- 2020-12-15 MX MX2022007222A patent/MX2022007222A/es unknown
- 2020-12-15 KR KR1020227023638A patent/KR20220116221A/ko unknown
- 2020-12-15 EP EP20901966.0A patent/EP4077398A4/en active Pending
- 2020-12-15 WO PCT/CN2020/136570 patent/WO2021121228A1/en unknown
- 2020-12-15 CA CA3163794A patent/CA3163794A1/en active Pending
-
2022
- 2022-06-09 ZA ZA2022/06438A patent/ZA202206438B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3163794A1 (en) | 2021-06-24 |
KR20220116221A (ko) | 2022-08-22 |
CN115052901A (zh) | 2022-09-13 |
US20230058669A1 (en) | 2023-02-23 |
IL293862A (en) | 2022-08-01 |
AU2020404272A1 (en) | 2022-06-23 |
ZA202206438B (en) | 2023-10-25 |
EP4077398A4 (en) | 2024-04-10 |
EP4077398A1 (en) | 2022-10-26 |
JP2023505719A (ja) | 2023-02-10 |
MX2022007222A (es) | 2022-09-21 |
WO2021121228A1 (en) | 2021-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022011666A2 (pt) | Receptor de antígeno quimérico, ácido nucleico isolado, vetor, célula imune, composição farmacêutica, método de tratamento de uma doença, anticorpo | |
EA201890302A1 (ru) | Химерные рецепторы антигенов на основе однодоменных антител и способы их применения | |
BR112022015450A2 (pt) | Anticorpo monoclonal isolado ou fragmento de conexão ao antígeno dele, composição farmacêutica, ácido nucleico isolado, vetor, célula hospedeira, processo de produção de um anticorpo, proteína do receptor de antígeno quimérico (car), célula modificada, método para tratar ou melhorar o efeito de um câncer em um sujeito, método para potencializar a ativação de células t em um sujeito e método para modular o fenótipo de macrófagos m2a em um sujeito | |
BR112017020915A2 (pt) | ?anticorpo de mamífero isolado ou fragmento de ligação ao antígeno do mesmo, anticorpo caninizado ou fragmento de ligação ao antígeno caninizado do mesmo, anticorpo monoclonal caninizado ou fragmento de ligação ao antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo isolado, proteína de fusão, composição farmacêutica, e, método para diminuir a atividade de uma célula imune? | |
Unger et al. | Selection of nanobodies that block the enzymatic and cytotoxic activities of the binary Clostridium difficile toxin CDT | |
BR112018016697A2 (pt) | anticorpo revestido, quimérico ou humanizado, composição farmacêutica, e, método de tratamento. | |
BR112018076260A2 (pt) | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina | |
AU2018258045A1 (en) | Chimeric antibody/T-cell receptor constructs and uses thereof | |
BR112019006074A2 (pt) | heterodímero, método de produção do heterodímero, métodos de produção de um heterodímero, ácido nucleico, vetor ou sistema de vetores, célula, composição farmacêutica e método de tratamento ou prevenção de uma doença ou distúrbio em um sujeito em necessidade do mesmo | |
EA201892193A1 (ru) | Химерные рецепторы к flt3 и способы их применения | |
BR112015017778A2 (pt) | anticorpos que compreendem domínios constantes quiméricos, moléculas de ácido nucleico, vetor, célula e proteína de fusão do receptor fc | |
BRPI0919853B8 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente ao receptor de interleucina-4 humano (hil-4r) e seus usos | |
BRPI0812878C1 (pt) | anticorpo isolado ou parte funcional do mesmo, vetor, método para produzir um anticorpo ou uma parte funcional do mesmo, para produzir uma célula produtora de anticorpo e para produzir um anticorpo capaz de se ligar especificamente a rsv, composição, e, uso de um anticorpo ou parte funcional do mesmo ou de uma composição ou de vetor | |
BR112017022255A2 (pt) | anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica | |
PE20220278A1 (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d | |
BR112019011186A2 (pt) | conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor. | |
BR112016029372A2 (pt) | anticorpo isolado ou fragmento de ligação de antígeno do mesmo, molécula de ácido nucleico isolado, vetor, métodos para produzir um anticorpo isolado ou fragmento de ligação de antígeno do mesmo, para preparar um conjugado e para aliviar um sintoma de um câncer, conjugado, e, uso de um conjugado. | |
BR112018000696A2 (pt) | ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit? | |
BRPI0821682A2 (pt) | Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif. | |
MX2020010094A (es) | Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos. | |
BR112017006598A2 (pt) | anticorpo de repetições antidipeptídeo derivado de ser humano (dprs) | |
WO2019060750A3 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
WO2017124001A3 (en) | T cell receptor-like antibodies specific for foxp3-derived peptides | |
JP2017129381A5 (pt) | ||
BR112018072140A2 (pt) | anticorpos anti-basigin humanizados e uso dos mesmos |